HLB Group Appoints Former Samsung Biologics CEO Kim Tae-han as Bio Chairman

Kim Tae-han, Chairman overseeing the Bio Division at HLB Group. (Photo courtesy of HLB Group)

 

HLB Group announced on December 31 that it will appoint Kim Tae-han, former CEO of Samsung Biologics, as chairman overseeing its bio business effective January 1, as the group accelerates global expansion amid pivotal clinical and regulatory milestones. 

HLB is awaiting U.S. FDA decisions on its liver cancer combination therapy rivoceranib and camrelizumab, as well as lirafugratinib for bile duct cancer, and views this period as a critical inflection point to convert R&D and approval outcomes into sustainable growth. Kim, widely recognized for building Samsung Biologics into a leading global CDMO, is expected to leverage his strategic expertise and international network to strengthen group-wide alignment across research, commercialization, and global partnerships among HLB’s bio affiliates.

Read more: https://www.ittimes.com/news/articleView.html?idxno=82501

HLB Group Appoints Former Samsung Biologics CEO Kim Tae-han as Bio Chairman - IT타임스